Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
The role of the amino acid residue at alpha1:189 in the binding of neuromuscular blocking agents to mouse and human muscle nicotinic acetylcholine receptors.
Purohit PG
,
Tate RJ
,
Pow E
,
Hill D
,
Connolly JG
.
???displayArticle.abstract???
Nicotinic acetylcholine receptors (AChRs) are valuable therapeutic targets. To exploit them fully requires rapid assays for the evaluation of potentially therapeutic ligands and improved understanding of the interaction of such ligands with their receptor binding sites.A variety of neuromuscular blocking agents (NMBAs) were tested for their ability to inhibit the binding of [(125)I]alpha-bungarotoxin to TE671 cells expressing human muscle AChRs. Association and dissociation rate constants for vecuronium inhibition of functional agonist responses were then estimated by electrophysiological studies on mouse muscle AChRs expressed in Xenopus oocytes containing either wild type or mutant alpha1 subunits.The TE671 inhibition binding assay allowed for the rapid detection of competitive nicotinic AChR ligands and the relative IC(50) results obtained for NMBAs agreed well with clinical data. Electrophysiological studies revealed that acetylcholine EC(50) values of muscle AChRs were not substantially altered by non-conservative mutagenesis of phenylalanine at alpha1:189 and proline at alpha1:194 to serine. However the alpha1:Phe189Ser mutation did result in a 3-4 fold increase in the rate of dissociation of vecuronium from mouse muscle AChRs.The TE671 binding assay is a useful tool for the evaluation of potential therapeutic agents. The alpha1:Phe189Ser substitution, but not alpha1:Pro194Ser, significantly increases the rate of dissociation of vecuronium from mouse muscle AChRs. In contrast, these non-conservative mutations had little effect on EC(50) values. This suggests that the AChR agonist binding site has a robust functional architecture, possibly as a result of evolutionary 'reinforcement'.
Arias,
Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors.
2000, Pubmed
Arias,
Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors.
2000,
Pubmed
Aylwin,
Ligand-receptor interactions in the nicotinic acetylcholine receptor probed using multiple substitutions at conserved tyrosines on the alpha subunit.
1994,
Pubmed
,
Xenbase
Bartkowski,
Recent advances in neuromuscular blocking agents.
1999,
Pubmed
Befort,
A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.
2001,
Pubmed
Blount,
Molecular basis of the two nonequivalent ligand binding sites of the muscle nicotinic acetylcholine receptor.
1989,
Pubmed
Boulter,
Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family.
1987,
Pubmed
,
Xenbase
Bowman,
Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat.
1988,
Pubmed
Connolly,
Alpha 4-2 beta 2 and other nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs.
1992,
Pubmed
,
Xenbase
Davis,
Familial dementia caused by polymerization of mutant neuroserpin.
1999,
Pubmed
Fehmann,
A new mutation in the hepatocyte nuclear factor-1-alpha gene (P224S) in a newly discovered German family with maturity-onset diabetes of the young 3 (MODY 3). Family members carry additionally the homozygous I27L amino acid polymorphism in the HNF1 alpha gene.
2004,
Pubmed
Foldes,
The neuromuscular effects of ORG9426 in patients receiving balanced anesthesia.
1991,
Pubmed
Fu,
Competitive antagonists bridge the alpha-gamma subunit interface of the acetylcholine receptor through quaternary ammonium-aromatic interactions.
1994,
Pubmed
Gallivan,
Cation-pi interactions in structural biology.
1999,
Pubmed
Garland,
The actions of muscle relaxants at nicotinic acetylcholine receptor isoforms.
1998,
Pubmed
,
Xenbase
Gotti,
Brain neuronal nicotinic receptors as new targets for drug discovery.
2006,
Pubmed
Jeevendra Martyn,
Muscle relaxants in burns, trauma, and critical illness.
2006,
Pubmed
Jonsson,
Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade.
2006,
Pubmed
,
Xenbase
Jou,
Novel CLCN1 mutations in Taiwanese patients with myotonia congenita.
2004,
Pubmed
Kindler,
Additive inhibition of nicotinic acetylcholine receptors by corticosteroids and the neuromuscular blocking drug vecuronium.
2000,
Pubmed
,
Xenbase
Lukas,
Characterization of curaremimetic neurotoxin binding sites on membrane fractions derived from the human medulloblastoma clonal line, TE671.
1986,
Pubmed
Luther,
A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671.
1989,
Pubmed
MacLennan,
Human nicotinic acetylcholine receptor alpha-subunit isoforms: origins and expression.
1993,
Pubmed
Min,
Iontophoretic study of speed of action of various muscle relaxants.
1992,
Pubmed
Ohno,
Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit.
1996,
Pubmed
O'Leary,
Mutational analysis of ligand-induced activation of the Torpedo acetylcholine receptor.
1992,
Pubmed
,
Xenbase
Palma,
Neuronal nicotinic alpha 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine.
1996,
Pubmed
,
Xenbase
Paul,
The potency of new muscle relaxants on recombinant muscle-type acetylcholine receptors.
2002,
Pubmed
,
Xenbase
Pedersen,
d-Tubocurarine binding sites are located at alpha-gamma and alpha-delta subunit interfaces of the nicotinic acetylcholine receptor.
1990,
Pubmed
Savarese,
The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.
1988,
Pubmed
Schoepfer,
The human medulloblastoma cell line TE671 expresses a muscle-like acetylcholine receptor. Cloning of the alpha-subunit cDNA.
1988,
Pubmed
Shanks,
Dose-response curves for four neuromuscular blockers using continuous i.v. infusion.
1981,
Pubmed
Smith,
Potency of succinylcholine at the diaphragm and at the adductor pollicis muscle.
1988,
Pubmed
Son,
A comparison of the neuromuscular blocking and vagolytic effects of ORG NC45 and pancuronium.
1981,
Pubmed
Spitzmaul,
Mechanistic contributions of residues in the M1 transmembrane domain of the nicotinic receptor to channel gating.
2004,
Pubmed
Steinlein,
A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy.
1995,
Pubmed
Stratton,
Misidentified cell.
1989,
Pubmed
Syapin,
Neuronal-like features of TE671 cells: presence of a functional nicotinic cholinergic receptor.
1982,
Pubmed
Takagi,
Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers.
2000,
Pubmed
Vanik,
Disease-associated F198S mutation increases the propensity of the recombinant prion protein for conformational conversion to scrapie-like form.
2002,
Pubmed
Weyand,
Crystal structure of the beta Ser178--> Pro mutant of tryptophan synthase. A "knock-out" allosteric enzyme.
2002,
Pubmed
Wierda,
Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487.
1994,
Pubmed
Yohannan,
The evolution of transmembrane helix kinks and the structural diversity of G protein-coupled receptors.
2004,
Pubmed
Yost,
Potency of agonists and competitive antagonists on adult- and fetal-type nicotinic acetylcholine receptors.
1997,
Pubmed
,
Xenbase
Zehelein,
Identification and characterisation of a novel KCNQ1 mutation in a family with Romano-Ward syndrome.
2004,
Pubmed
,
Xenbase
Zhong,
From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor.
1998,
Pubmed
